Program
RAS Inhibitor AN9025
Its studies are led by Adlai Nortye Biopharma.
Furthest: phase 1, since Nov 14, 20251 company-led study, 1 open or runningNext primary completion: Jan 31, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Adlai Nortye Biopharma | 11 open or running | phase 1since Nov 14, 2025 | Nov 14, 2025 | Jan 31, 2028phase 1 · NCT07252479 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 14, 2025First study: phase 1 study in Solid Tumors (Phase 1)First studyNCT07252479 · 118 planned · United States
Ahead
- Jan 31, 2028Primary completion: phase 1 study in Solid Tumors (Phase 1)NCT07252479
TargetBeta
“An orally bioavailable inhibitor of the active, guanosine triphosphate (GTP)-bound form of both wild type and mutant variants of the RAS isoforms, including NRAS and KRAS, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07252479Solid Tumors (Phase 1) · United States | 1 | Recruiting | Jan 31, 2028 | 118 |
How it is read
Names in the registry
- “AN9025 oral capsule”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.